Clients

Genprex, Inc.

Company Snapshot: Genprex, Inc.

GNPX
Last Change Volume High Low

Company Overview

Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Client News

  1. May 31 2019 Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Gene Therapy as Potential Cancer Treatment
  2. May 30 2019 Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Hunt for Gene Therapy Breakthroughs  
  3. May 30 2019 Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Hunt for Gene Therapy Breakthroughs  
  4. May 30 2019 Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Hunt for Gene Therapy Breakthroughs  
  5. May 21 2019 Genprex to Present at Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum